IL6 and breast carcinoma: Moreover, IL-6 has also been reported to correlate with therapeutic resistance in breast cancer patients highlighting the IL-6/JAK/STAT3 pathway as an important prognostic marker in breast cancer progression, chemoresistance, and metastatic formation (78).